Skip to content
Open access

Epigenetic dysregulation of Th2 cytokine genes in MuSK myasthenia gravis and its modulation by immunosuppressive therapy

Aug 2026 · bioRxiv · 0 citations · 44 references
Biology

TL;DR

A role for epigenetic dysregulation of Th2-associated cytokines in the immunological environment associated with IgG4 subclass switch is support by this first study investigating IL4, IL10, and IL13 promoter DNA methylation in MuSK-MG.

Abstract

Background and objectives Myasthenia gravis associated with antibodies against muscle-specific kinase (MuSK-MG) is a well-characterized IgG4-autoimmune disease, however, the mechanisms driving IgG4 predominance remain poorly understood. This study investigated whether promoter DNA methylation of cytokine genes involved in IgG4 class switching is associated with this immune response. Methods Peripheral blood mononuclear cells were isolated from MuSK-MG patients (n=36), acetylcholine receptor myasthenia gravis (AChR-MG) patients as disease controls (n=7), and sex-matched healthy controls (n=12). Promoter DNA methylation of IL4, IL10, and IL13 was assessed by methylation-sensitive high-resolution melting and relative cytokine mRNA expression by qPCR. Associations with clinical variables, and antibody levels were subsequently evaluated. Results MuSK-MG patients showed lower median IL13 promoter methylation compared with healthy controls (p = 0.004). Median IL4 promoter methylation was also reduced in MuSK-MG compared with healthy controls (p < 0.001) and AChR-MG disease controls (p < 0.001), whereas no differences were observed for IL10 promoter methylation. Relative mRNA expression of IL4 (p = 0.0005), IL10 (p = 0.0462), and IL13 (p = 0.0002) was increased in MuSK-MG compared with AChR-MG. Compared with healthy controls, only IL4 expression remained significantly increased (p < 0.0001). Promoter methylation was inversely correlated with relative mRNA expression for IL4 (p < 0.0001), while IL13 showed a similar but non-significant trend (p = 0.054), no association was observed for IL10. Multivariable analysis demonstrated that treatment at sampling was independently associated with lower IL10 and IL13 promoter methylation, whereas no associations were observed with age, sex, disease phase, or disease duration. Promoter methylation did not correlate with total serum IgG4 or anti-MuSK IgG4 levels. Discussion MuSK-MG is associated with selective hypomethylation of IL4 and IL13 promoters accompanied by increased cytokine gene expression, while IL10 promoter methylation remains unchanged. The association between treatment and IL10 and IL13 promoter methylation suggests that immunosuppressive therapy may influence epigenetic regulation in MuSK-MG. Together, these findings support a role for epigenetic dysregulation of Th2-associated cytokines in the immunological environment associated with IgG4 subclass switch. To our knowledge, this is the first study investigating IL4, IL10, and IL13 promoter DNA methylation in MuSK-MG.

Read PDF

Similar papers

Review Open access Aug 2026

The immune microenvironment and population heterogeneity in myasthenia gravis: implications for precision therapeutics

Current evidence on the roles of the immune microenvironment and individual heterogeneity in shaping the pathogenesis and treatment landscape of Myasthenia gravis is discussed, emphasizing the transition from phenotype-based disease classification toward immune endotype-driven precision medicine within population heter...

Xia Xue, Chang Liu, Chunjing Qiu et al. · 0 citations
Open access Oct 2026

A potential biomarker for the efficacy of complement inhibitors in myasthenia gravis.

BACKGROUND In acetylcholine receptor (AChR) antibody-positive myasthenia gravis (MG), complement activation is a major mechanism underlying impaired neuromuscular transmission and complement inhibitors are used in clinical practice. In the absence of biomarkers predicting responsiveness to complement inhibitors, this s...

Etsuko Ogaya, A. Uzawa, Hiroyuki Akamine et al. · 0 citations
Open access Oct 2026

Dual-Axis Pattern of Peripheral Immunity in Myasthenia Gravis Susceptibility: A Prospective Cohort Study and Mendelian Randomization Analysis

Background: Previous studies have revealed peripheral immune abnormalities in myasthenia gravis (MG). However, it remains uncertain whether these abnormalities precede the onset of clinical symptoms and affect susceptibility to MG. Methods: A prospective study was performed involving 420,936 UK Biobank participants wit...

Jiang Lei, Hao Huang, Jia-Xin Chen et al. · 0 citations
Open access Oct 2026

Potential association between Epstein-Barr virus infection and myasthenia gravis.

PURPOSE Epstein-Barr virus (EBV) has been implicated in multiple autoimmune disorders; however, its role in myasthenia gravis (MG) remains incompletely defined. We investigated EBV nuclear antigen 1 (EBNA-1)-specific humoral immunity in MG and examined whether human leukocyte antigen (HLA) genotypes modulate this assoc...

Na-Na Zhang, Xue Lin, Hong-Xi Chen et al. · 0 citations
Open access Sep 2026

Dysregulation of the cytotoxic-humoral axis and expansion of regulatory T cells in anti-TIF1γ- positive dermatomyositis

Introduction Dermatomyositis (DM), particularly the anti-TIF1γ‑positive subtype, is associated with a substantially elevated risk of malignancy. However, the peripheral immune landscape of this autoantibody-defined subset, especially in patients without concurrent cancer, remains incompletely understood. Methods We per...

Xiao-Guang Cui, Kai-Hong Ye, Hong Wang et al. · 0 citations
Open access Sep 2026

Autoantibody Profiles of Immune Checkpoint Inhibitor-Associated Myasthenia and Myositis

Introduction Immune checkpoint inhibitor (ICI)-associated myasthenia and myositis are rare, potentially life-threatening neuromuscular immune-related adverse events, but their serological spectrum remains incompletely characterized. This study aimed to elucidate their autoantibody profiles and explore associations with...

T. Kawazoe, T. Tezuka, Keisuke Ishizawa et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.